相关实验视频
Updated: May 20, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
940
布里加替尼激活炎症酶:与免疫相关的不良事件有关
Takumi Noda1, Saori Tanaka1, Yuto Maruta1
1Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka 569-1094, Japan.
Toxicology and applied pharmacology
|March 23, 2025
概括
布里加替尼 (Brigatinib) 是一种ALK抑制剂,直接激活炎症体,引起免疫反应. 这种药物诱导的肝细胞炎酶激活可能解释了布里加替尼的存在.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 无细胞淋巴瘤激酶 (ALK) 氨酸激酶抑制剂 (TKI) 治疗ALK阳性非小细胞肺癌.
- 布里加替尼 (Brigatinib) 是一种与可能涉及免疫激活的严重不良反应相关的ALK TKI.
- 不完全理解布里加替尼诱导的免疫相关不良影响的机制.
研究的目的:
- 调查布里加替尼和其他ALK TKIs直接激活炎酶的情况.
- 为了分析药物治疗的肝细胞超标的炎症酶激活.
- 阐明布里加替尼在免疫相关不良事件中的作用.
主要方法:
- 差异化THP-1细胞被用于评估布里加替尼和其他ALK TKIs (克里佐替尼,阿莱克替尼,谢里替尼) 的直接炎症酶激活.
- 用这些药物治疗的功能性肝细胞 (FLC) -4细胞的超级活体被分析为炎酶激活潜力.
- 测量了FLC-4细胞超级生物中损伤相关分子模式 (DAMPs) 的水平.
主要成果:
- 布里加替尼直接激活THP-1细胞中的炎症体,诱导IL-1β的产生和caspase-1的激活.
- 其他ALK TKIs没有诱导炎症酶激活.
- 来自布里加替尼治疗的FLC-4细胞的余物激活了THP-1细胞中的炎症体.
- 布里加替尼 (Brigatinib) 在FLC-4细胞超体中增加了DAMP (HSP90,S100A6).
结论:
- 布里加替尼直接激活炎症酶,与其他ALK TKIs不同.
- 布里加替尼诱导肝细胞释放DAMP,然后激活炎症细胞.
- 这种DAMP介导的炎症酶激活途径可能是布里加替尼诱导的免疫相关不良事件的基础.
更多相关视频
相关概念视频
Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
The Intrinsic Apoptotic Pathway
5.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
Activation of Integrins
3.2K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.2K
Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K

